Compounders sue US FDA over semaglutide ruling
A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the agency acted unlawfully when it removed Novo Nordisk’s (NOV: N) semaglutide-based drugs Ozempic (semaglutide) and Wegovy (semaglutide) from the official shortage list.
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...
Semaglutide — the type 2 diabetes and weight loss medication sold under the brand names Ozempic and Wegovy — can expire. If ...
People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.
Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
healthday on MSN21h
Nonarteritic Anterior Ischemic Optic Neuropathy Increased With SemaglutideFor individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...
“As time goes on, they’re more willing to share their story because they get so many compliments,” she said. “The person who is next to them says, ‘Tell me your secret,’ and they may whisper my name ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback